“Researchers at Johns Hopkins University are conducting the first clinical trials to evaluate the potential of a pinworm medication for the treatment of children and adults with newly diagnosed glioblastoma.
“Mebendazole has been used for more than 40 years to treat parasitic infections.
“Although the medication requires further testing in patients with cancer, results of a phase 1 trial have shown the medication is safe for and tolerated by adults with glioblastoma. An additional phase 1 trial is underway to assess the agent in children.”
“The most common type of malignant childhood brain cancer has been identified as seven separate conditions each needing a different treatment, new research has revealed.
“A study by Newcastle and Northumbria universities has found that childhood medulloblastoma can be separated into seven different subgroups which all have their own biological and clinical characteristics.”
“A team of investigators has determined that young children participating in a clinical trial to assess the effectiveness of reduced radiotherapy did worse when there were deviations from the treatment protocol. Results of the study will be available online in advance of publication by Pediatric Blood & Cancer on April 4.
” ‘This study shows that attention to the timing, dose, and location of radiation therapy is crucial,’ Kenneth K. Wong, MD, a radiation oncologist at Children’s Hospital Los Angeles and first author on the study.
“Robert H. Lurie Children’s Hospital of Chicago have revealed new insight into how the most deadly pediatric brain tumor, diffuse intrinsic pontine glioma (DIPG), may develop. They also have identified a compound that targets the ‘on’ switch for cancer-promoting genes, which resulted in shrinking tumor size and increased survival in an animal model of DIPG. Preparations for a clinical trial at Lurie Children’s are now under way.”
“Results from a large clinical study showed that testing pediatric brain tumors for genetic abnormalities is feasible and could play a role in guiding patients’ treatment.
“The study, published in Neuro-Oncology, showed that more than half of the samples taken from pediatric brain tumors and analyzed using genomic profiling had genetic irregularities that could influence how the disease was diagnosed or treated with approved drugs or agents being evaluated in clinical trials.”
Los Altos, California – January 25, 2017 – Cancer Commons, a nonprofit network of physicians, scientists and patients dedicated to helping each patient achieve the best possible outcome, announces the launch of a new program to identify personalized treatment options for children with brain cancer. The program is funded by a generous lead gift from Sheri Sobrato Brisson, a pediatric brain tumor survivor and advocate for children with serious illness, and her husband Eric Brisson.
“We are motivated to help children with brain cancer by giving their physicians and families access to the best treatment plans,” shares Sheri Sobrato Brisson. “Diagnosis is a frightening time, and patients and their families need help to quickly sort through vast, confusing amounts of information to assure them that they are making the best possible choices.” Continue reading…
“A team of Dana-Farber scientists has released new research with an important message about precision medicine: Sequencing the genes of brain tumors in kids could point to treatments that target their genetic abnormalities and therefore have the best chance of being effective. At least one of those drugs is already on the market, Novartis’ Tafinlar (dabrafenib), approved by the FDA to treat other types of cancer but still readily available to pediatric oncologists who may want to try it in their patients.”